13F filer · CIK 1974915
Vestal Point Capital, LP
NEW YORK, NY · filing since Q4 2023 · last filing Aug 14, 2026
Reported value
$4.3B
+$702.6M vs prior
Positions
68
New / sold out
11 / 33
Added / reduced
31 / 21
Turnover
39.4%
buys $1.6B · sells $1.5B
Top-10 weight
50.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | United Therapeutics Corp | +360,000 | +480.0% | +$195.1M |
| Added | BioMarin Pharmaceutical Inc | +2,450,000 | +68.5% | +$140.2M |
| New | Abbott Laboratories | +1,400,000 | – | +$127.0M |
| Added | Abivax SA | +849,443 | +56.6% | +$113.2M |
| Added | Neurocrine Biosciences Inc | +630,000 | +50.4% | +$106.2M |
| Added | Zimmer Biomet Holdings Inc | +1,210,000 | +636.8% | +$104.2M |
| New | Ascendis Pharma A/S | +375,000 | – | +$100.0M |
| Added | Insulet Corp | +619,399 | +1224.1% | +$94.3M |
| Added | AstraZeneca PLC | +350,000 | +350.0% | +$66.4M |
| Added | Disc Medicine Inc | +850,000 | +121.4% | +$62.2M |
32 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Revolution Medicines Inc | -1,925,000 | -81.1% | $-360.5M |
| Sold out | Apogee Therapeutics Inc | -1,100,000 | -100.0% | $-92.6M |
| Sold out | Ascendis Pharma A/S | -375,000 | -100.0% | $-85.8M |
| Reduced | Repligen Corp | -525,000 | -56.8% | $-71.6M |
| Sold out | Scholar Rock Holding Corp | -1,324,422 | -100.0% | $-65.1M |
| Reduced | Arrowhead Pharmaceuticals Inc | -700,000 | -30.8% | $-57.1M |
| Sold out | Vera Therapeutics Inc | -1,368,159 | -100.0% | $-55.0M |
| Sold out | Terns Pharmaceuticals Inc | -1,000,000 | -100.0% | $-52.7M |
| Sold out | Boston Scientific Corp | -800,000 | -100.0% | $-50.2M |
| Sold out | Nuvalent Inc | -481,715 | -100.0% | $-49.4M |
44 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | BioMarin Pharmaceutical IncCOM | 6,025,000 | $344.8M | 8.06% |
| 2 | Neurocrine Biosciences IncCOM | 1,880,000 | $316.8M | 7.40% |
| 3 | Abivax SASPONSORED ADS | 2,349,443 | $313.1M | 7.32% |
| 4 | United Therapeutics CorpCOM | 435,000 | $235.7M | 5.51% |
| 5 | Enliven Therapeutics IncCOM | 4,000,000 | $203.0M | 4.74% |
| 6 | Nurix Therapeutics IncCOM | 8,050,000 | $195.3M | 4.56% |
| 7 | Bicara Therapeutics IncCOM | 5,250,000 | $155.9M | 3.64% |
| 8 | Taysha Gene Therapies IncCOM SHS | 19,415,000 | $132.2M | 3.09% |
| 9 | Arrowhead Pharmaceuticals IncCOM | 1,575,000 | $128.4M | 3.00% |
| 10 | Abbott LaboratoriesCOM | 1,400,000 | $127.0M | 2.97% |
58 more rows. Subscribe for $29/month to see every row, download the data and use the API.